Who We Are
Kincell Bio is a leading cell therapy CDMO
Delivering reliable, right-first-time manufacturing from early clinical to commercial launch. By combining deep scientific expertise with personalized service and purpose-built U.S. facilities, we act as a transparent extension of your team to ensure scalable, high-quality supply.
CDMO Services
Integrated Solutions Supporting Commercially Viable Cell Therapies
CMC
CMC Roadmap & Development
Charting and executing full lifecycle CMC roadmaps and process development strategies that drive control, scalability, and regulatory success.
Analytics
Testing
Process Development
Manufacturing
Tech Transfer
Full Lifecycle Support
Transforming Cell Therapy Innovation into Commercial Reality
Early-Phase Acceleration
Early-Phase Acceleration
Kincell accelerates early-phase cell therapy programs through risk-managed CMC roadmaps, DoE-driven process optimization, and phase-appropriate analytics, aligning rapid IND readiness with long-term commercial strategy to deliver clinical material efficiently and confidently.
Late-Phase Development
Commercialization & Commercial Supply
Insights & Updates
Explore Kincell’s latest news and expert insights, and catch up with us at upcoming industry events.
How to Build a Cell Therapy CMC Roadmap
Cell therapies that have reached the market are changing lives. The potential to have such an impact drives sponsors to face the...
Articles
Kincell Bio on Why It’s Expanding Its Research Triangle Park Facility at a Time Other Cell Therapy CDMOs are Retracting
For cell therapy programs approaching commercialization, a CDMO’s infrastructure can make or break their timeline. Hear from Kincell Bio’s leadership team on...
Talk to an expert
Turning Cell Therapy Innovation Into Patient Impact
Leveraging our science-first expertise and right-first-time quality, partner with Kincell Bio to advance your cell therapy from concept to commercialization.
"*" indicates required fields